Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.33 |
| ▸ | KCNK13 | Q9HB14 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26923796 | 0.78 | CCR1 (0.37) | EGLN2KCNK13 | |
| SCHEMBL16478722 | 0.78 | CYP2A6 (0.35) | EGLN2KCNK13 | |
| SCHEMBL3294798 | 0.78 | EGLN2 (0.41) | EGLN2ALDH1A1 | |
| SCHEMBL3293340 | 0.78 | ALDH1A1 (0.41) | ALDH1A1 | |
| Hydrochloric Acid SCHEMBL26921435 | 0.77 | LOXL2 (0.34) | EGLN2KCNK13 | |
| Hydrochloric Acid SCHEMBL26921638 | 0.77 | LOXL2 (0.34) | EGLN2KCNK13 | |
| SCHEMBL30942641 | 0.75 | TKT (0.33) | EGLN2KCNK13 | |
| SCHEMBL30942638 | 0.74 | EGLN2 (0.30) | EGLN2KCNK13 | |
| SCHEMBL732152 | 0.70 | — | — | |
| SCHEMBL9297038 | 0.68 | SOS2 (0.39) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170037028-A1 | GLUCOSE TRANSPORT INHIBITORS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-02-09 | — | — | US | disclosed |
| EP-3083598-A1 | GLUCOSE TRANSPORT INHIBITORS | Bayer Pharma Aktiengesellschaft (DE) | 2016-10-26 | — | — | EP | disclosed |
| CN-106029647-A | Glucose transport inhibitors | 拜耳制药股份公司 | 2016-10-12 | — | — | CN | disclosed |
| WO-2015091428-A1 | GLUCOSE TRANSPORT INHIBITORS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-06-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170037028-A1 | GLUCOSE TRANSPORT INHIBITORS | SLC2A1, SLC2A2, SLC2A4 | EGLN2 378/4885KCNK13 3219/4885ALDH1A1 432/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.